Reaction

Lymphoproliferative Disorder reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,902 reports · 58 co-occurring drugs

As of the last recalculation, Lymphoproliferative Disorder appears in 2,902 FAERS reports alongside 58 co-occurring drug terms. The strongest observed disproportionality signal is METHOTREXATE SODIUM (PRR 44.9).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Methotrexate Sodium	1,503	44.9	45.1
Methotrexate	1,070	28.3	28.4
Prednisolone	514	24.6	24.7
Prednisolone Oral	514	24.6	24.7
Prednisolone Oral Solution	514	24.6	24.7
Anti-Thymocyte Globulin (Rabbit)	27	24.2	24.3
Ganciclovir	29	20.5	20.6
Ganciclovir Sodium	29	19.8	19.9
Azathioprine	225	19.8	19.8
Alemtuzumab	51	19.2	19.3
Tacrolimus	352	18.2	18.2
Fludarabine Phosphate	92	17.3	17.3
Cyclosporine	231	16.1	16.1
Tacrolimus Ointment 0.1%	247	15.5	15.5
Tacrolimus Extended-Release Capsules	247	15.4	15.4
Mycophenolate Mofetil Hydrochloride	267	15.4	15.4
Mycophenolate Mofetil	264	15.2	15.3
Testosterone	48	15.0	15.0
Busulfan	32	14.7	14.8
Basiliximab	22	13.5	13.5
Melphalan	40	12.8	12.8
Melphalan Hydrochloride	41	11.9	11.9
Sirolimus	22	11.8	11.8
Tofacitinib Citrate	20	11.0	11.0
Baricitinib	14	10.5	10.5
Cyclophosphamide Injection, Solution	238	10.4	10.4
Cyclophosphamide	238	10.4	10.4
Cyclophosphamide For Injection	238	10.4	10.4
Infliximab	281	10.1	10.1
Adalimumab-Fkjp	60	9.5	9.5
Adalimumab-Aaty	60	9.3	9.3
Thiotepa	12	9.0	9.1
Bleomycin Sulfate	12	8.4	8.4
Adalimumab-Adaz	60	8.3	8.3
Enalapril Maleate	28	8.2	8.2
Enalapril	61	8.0	8.0
Mercaptopurine	18	7.5	7.5
Mycophenilic Acid	20	7.0	7.0
Axicabtagene Ciloleucel	9	6.6	6.6
Sulfasalazine	70	6.6	6.6
Polatuzumab Vedotin	8	5.9	5.9
Rituximab	161	5.7	5.7
Mycophenolic Acid	25	5.6	5.6
Bendamustine Hcl	12	5.6	5.6
Golimumab	63	5.4	5.4
Doxorubicin	64	5.2	5.2
Mesna Injection	6	5.2	5.2
Mesna	6	5.1	5.1
Micafungin Sodium	6	5.1	5.1
Etoposide	46	4.5	4.5
Cladribine	6	4.5	4.5
Tocilizumab	66	4.2	4.2
Brentuximab Vedotin	6	4.2	4.2
Ifosfamide	12	4.0	4.0
Romiplostim	7	3.3	3.3
Abatacept	63	3.3	3.3
Sarilumab	10	2.7	2.7
Ranitidine	61	2.2	2.2

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.